Series Studies of Bipolar Disorder-Valproate add-on Memantine
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
All participants should fulfill the following criteria: aged between 18 and 65 years old, and
of domestic Han descendants. Participants will be randomly assigned to either the (1)
pharmacotherapy (valproate add-on memantine) group; (2) pharmacotherapy (valproate add-on
memantine) plus Cognitive Behavior Group Therapy (CBGT) group; (3) valproate add-on placebo
plus CBGT group, or (4) valproate add-on placebo only group. A total of 240-320 individuals
(60-80 participants per group) will be recruited for this study. For each CBGT group,
12-weekly sessions are scheduled according to patients' preference. The investigators will
attempt to understand the effects of pharmaceutical drugs for mood stabilizers add-on
neuro-protective drugs, pharmacotherapy with CBGT, mood stabilizer with CBGT, and the use of
only traditional mood stabilizers in the treatment of BP II. Comparisons will be made for
each type of treatment and possible mechanisms will be examined regarding the pharmacotherapy
and CBGT for bipolar disorder patients.